

CytoDyn Inc.

07:59 23 Dec 2019

CytoDyn's leronlimab sees strong positive clinical responses in two patients with metastatic breast cancer and mTNBC

CytoDyn Inc (OTCMKTS:CYDY) announced Monday continued promising clinical responses from its metastatic triple-negative breast cancer (mTNBC) Phase1b/2 trial and its trial investigating leronlimab for the treatment of metastatic breast cancer (MBC).

In a statement, the Vancouver, Washington-based late-stage biotechnology company said the first enrolled metastatic triple-negative breast cancer patient shows no detectable circulating tumor cells (CTC) or putative metastatic tumor cells in the peripheral blood and additional reductions in CCR5 expression on cancer-associated cells at 11 weeks of treatment with leronlimab.

A second patient with metastatic breast cancer has been enrolled in the trial under an emergency use investigational new drug (IND) process and additional data in the patient demonstrated shrinkage of tumor (via MRI) after three weeks of treatment with leronlimab.

READ: CytoDyn sees positive results as first triple-negative breast cancer patient treated with leronlimab

"In the first patient, we're encouraged to see that after 11 weeks these additional data provide further preliminary evidence of efficacy, as demonstrated by sustained undetectable levels of CTCs and a reduction of cancer-associated macrophage like cells (CAMLs)," said IncellDx CEO Bruce Patterson.

"Thus far, the data have been consistent with previous studies evaluating leronlimab as a long-term therapy for HIV+ patients, with no serious adverse effects reported in the mTNBC trial," he added.

CytoDyn's second patient enrolled is a stage 4 metastatic breast cancer patient. The metastasis progressed to the liver, lung and brain. This patient was enrolled through an emergency IND. The patient was on Herceptin and Perjeta for over 1.5 years. Herceptin is known to stop working after about 12 months, while Perjeta is effective for roughly 1.5 years. This patient received her first injection of leronlimab on November 25, with one 700 mg dose each week.

"It is very exciting to see ongoing results that demonstrate leronlimab's potential as a therapeutic option to treat patients with mTNBC and MBC with HER2+ condition. This second patient was enrolled in an emergency IND," said CytoDyn CEO Nader Pourhassan.


"The results from two subsequent scans of the metastatic lesions for this second patient demonstrated shrinkage of the tumors at both timepoints following the first leronlimab injection, reduction in brain edema, and remarkably, disappearance of several metastatic tumors," he added.

The CytoDyn boss said that due to the "very promising clinical data," the company feels that the 98% inhibition of

Price: 3.07

Market Cap: \$1.32 billion

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: CYDY

Listing: OTCQB

52 week High Low
3.5 0.261

Sector: Pharma & Biotech

Website: www.cytodyn.com

Company Synopsis:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man.

action@proactiveinvestors.com

metastasis shown by animal studies may soon become a reality for many cancer patients throughout the world.

"We are cautiously optimistic and believe we have enough results in an unmet medical need population to justify filing for Breakthrough Therapy Designation in January 2020," said Pourhassan.

Leronlimab blocks CCR5, a cellular receptor, which has found to be important in HIV infection, tumor metastases, and other diseases including non-alcoholic fatty liver disease (NASH).

CytoDyn is developing leronlimab to battle multiple diseases. The company has filed an IND application and a Phase 2 clinical trial protocol with the US Food and Drug Administration for leronlimab to treat patients with non-alcoholic steatohepatitis (NASH).

Leronlimab has also already completed nine clinical trials and been given to 800 patients in HIV treatment programs, without a single drug-related serious adverse event. CytoDyn is also exploring leronlimab's use in the treatment of inflammatory conditions and autoimmune diseases.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).